A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
Clinical trial NCT07290166 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07290166
- Sponsor
- Fudan University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-31
- Primary completion
- 2027-10-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.